Medicube was ordered by South Korean regulators to suspend advertising for certain products in early 2026 due to violations of the Cosmetics Act.
The ads for "One Day Exosome Pore Ampoule 2000" and "One Day Exosome Shot Pore Ampoule 7500" were ordered to be suspended until June 8, 2026. Regulators found that Medicube used expressions in their advertisements that could mislead consumers into believing the cosmetics were pharmaceutical products (over-advertising). This action is part of a broader crackdown by the Korean Ministry of Food and Drug Safety (MFDS) on exaggerated "medical-lite" claims, including "pore improvement" and "skin regeneration" in the booming exosome and PDRN skincare market.
Medicube accepted the administrative action and pledged to provide more accurate information to consumers. This incident is part of increasing scrutiny on K-Beauty brands using aggressive marketing techniques around high-functionality ingredients.
